Evommune, Inc. (EVMN) shareholders
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
$7.63−0.39 (-4.86%)
Close on Nov 13, 2026Market cap $276.91MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
95.4%
35M of 36M shares
Institutional holders
105
41 new, 17 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
3 buys · 9 sales
Net sold $2.12M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| LSP 7 Cooperatieve U.A. Joint filing with LSP 7 Management B.V. (14.70%) | 5,288,313 | 14.70% | 13D (active) amendment | Feb 12, 2026 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (8.50%), Rajeev Shah (8.50%) and 1 more | 3,494,638 | 8.50% | 13D (active) amendment | Nov 6, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.70%), Peter Kolchinsky (9.70%) and 1 more | 3,494,638 | 9.70% | 13D (active) amendment | Feb 12, 2026 |
| Nan Fung Group Holdings Limited Joint filing with NF Investment Holdings Limited (10.70%), Nan Fung Life Sciences Holdings Limited (10.70%) and 5 more | 3,435,599 | 10.90% | 13G (passive) | Dec 31, 2025 |
| T. Rowe Price Associates, Inc. | 1,940,939 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Point72 Capital Advisors, Inc. Joint filing with Point72 Asset Management, L.P. (5.30%), Steven A. Cohen (5.30%) | 1,910,489 | 5.30% | 13G (passive) | Jul 15, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EVMN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 5,288,313 | 14.57% | $70.28M | +358,680 | 8.15% |
| Ra Capital Management, L.P. | 3,494,638 | 9.63% | $46.44M | – | 0.40% |
| Price T Rowe Associates Inc /Md/ | 1,940,939 | 5.35% | $25.80M | +821,918 | 0.00% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,926,943 | 5.31% | $25.61M | – | 8.32% |
| JPMorgan Chase & Co | 1,553,132 | 4.28% | $23.37M | +93,712 | 0.00% |
| Rtw Investments, LP | 1,502,235 | 4.14% | $19.96M | – | 0.17% |
| Nan Fung Group Holdings Ltd | 1,441,032 | 3.97% | $19.15M | – | 14.56% |
| Point72 Asset Management, L.P. | 1,435,049 | 3.95% | $19.07M | +1,398,472 | 0.02% |
| Andera Partners | 1,391,990 | 3.84% | $18.50M | −505,372 | 8.96% |
| Eventide Asset Management, LLC | 1,209,129 | 3.33% | $16.07M | – | 0.21% |
| Vestal Point Capital, LP | 1,000,000 | 2.76% | $13.29M | New | 0.31% |
| Jupiter Topco LLC | 896,700 | 2.47% | $11.92M | New | 0.00% |
| BlackRock, Inc. | 886,538 | 2.44% | $11.78M | +212,967 | 0.00% |
| Vanguard Capital Management LLC | 881,895 | 2.43% | $11.72M | +426,844 | 0.00% |
| Baker Bros. Advisors LP | 847,390 | 2.33% | $11.26M | – | 0.06% |
| Defilade Capital Management, L.P. | 793,145 | 2.19% | $10.54M | +114,556 | 1.41% |
| American Century Companies Inc | 755,018 | 2.08% | $10.03M | +262,080 | 0.00% |
| Alyeska Investment Group, L.P. | 704,425 | 1.94% | $9.36M | −21,937 | 0.02% |
| Balyasny Asset Management L.P. | 457,015 | 1.26% | $6.07M | New | 0.01% |
| Velan Capital Investment Management LP | 451,255 | 1.24% | $6.00M | +5,000 | 3.65% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 105 | 35M | 95.4% | 41 / 36 | 13 / 17 | 9M | 7M |
| Q1 2026 | 84 | 35M | 95.8% | 37 / 26 | 11 / 10 | 10M | 2M |
| Q4 2025 | 59 | 27M | 74.9% | 59 / 0 | 0 / 0 | 27M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of EVMN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Eventide Healthcare & Life Sciences Fund | 940,119 | 2.59% | $12.49M | 0.70% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 739,068 | 2.04% | $9.82M | 0.00% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 711,122 | 1.96% | $9.45M | 0.06% | Jun 30, 2026 |
| Small Cap Growth Fund | 567,828 | 1.56% | $6.39M | 0.11% | Jul 31, 2026 |
| JPMorgan Small Cap Growth Fund | 554,355 | 1.53% | $7.37M | 0.28% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 346,633 | 0.96% | $4.61M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 332,110 | 0.92% | $4.41M | 0.01% | Jun 30, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 325,000 | 0.90% | $3.66M | 0.13% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 258,200 | 0.71% | $3.43M | 0.03% | Jun 30, 2026 |
| JPMorgan Small Cap Blend Fund | 176,234 | 0.49% | $2.34M | 0.14% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 138,618 | 0.38% | $1.56M | 0.00% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 126,549 | 0.35% | $1.68M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 119,063 | 0.33% | $1.58M | 0.01% | Jun 30, 2026 |
| Multi-Manager Small Cap Equity Strategies Fund | 92,684 | 0.26% | $2.15M | 0.17% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 58,033 | 0.16% | $1.35M | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Luis C. Pena | President & CEO, Director | 631,573 | 1.74% | Oct 15, 2026 |
| Eugene Bauer | Chief Medical Officer, Director | 270,818 | 0.75% | Apr 17, 2026 |
| Kyle Carver | Chief Financial Officer | 60,335 | 0.17% | Jul 10, 2026 |
| Janice Suzann Drew | Chief of Dev. Operations | 71,633 | 0.20% | Jun 24, 2026 |
| Jeegar Pravinkumar Patel | Chief Scientific Officer | 46,403 | 0.13% | Jun 24, 2026 |
| Gregory S. Moss | Chief Business & Legal Officer | 64,010 | 0.18% | Jun 1, 2026 |
| Arthur S. Kirsch | Director | 10,000 | 0.03% | Jul 8, 2026 |
| Benjamin F. McGraw Iii | Director | – | – | Jun 3, 2026 |
| David E. Cohen | Director | 17,609 | 0.05% | Jun 3, 2026 |
| 7 Cooperative UA LSP | Director, 10% owner | 10,217,946 | 28.15% | Feb 19, 2026 |
| Weegen Felice Isabel Verduyn-van | Director, 10% owner | 5,288,313 | 14.57% | Feb 18, 2026 |
| Peter Kolchinsky | Director | – | – | Feb 17, 2026 |
| Capital Healthcare Fund LP RA | Director | 2,710,293 | 7.47% | Feb 17, 2026 |
| RA Capital Nexus Fund III, L.P. | Director | – | – | Feb 17, 2026 |
| Rajeev M. Shah | Director | – | – | Feb 17, 2026 |
| Ra Capital Management, L.P. | Director | 784,345 | 2.16% | Feb 17, 2026 |
| Robert Lorne Hopfner | Director, 10% owner | 3,372,001 | 9.29% | Dec 22, 2025 |
| Pivotal bioVenture Partners Fund I, L.P. | Director, 10% owner | – | – | Nov 12, 2025 |
| bioVenture Partners Fund I. U.G.P. Ltd Pivotal | Director, 10% owner | – | – | Nov 12, 2025 |
| Pivotal bioVenture Partners Fund I G.P., L.P. | Director, 10% owner | 294,502 | 0.81% | Nov 12, 2025 |
| Derek DiRocco | Director | – | – | Nov 5, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Luis C. Pena President & CEO, Director | Sep 30, 2026 | Award | +1,115 | $7.02 | $7.83K | 631,573 |
| Kyle Carver Chief Financial Officer | Jul 8, 2026 | Buy | +1,000 | $13.26 | $13.26K | 60,335 |
| Arthur S. Kirsch Director | Jul 7, 2026 | Buy | +10,000 | $13.30 | $133.00K | 10,000 |
| Luis C. Pena President & CEO, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −7,438 | $22.71 | $168.92K | 630,458 |
| Jeegar Pravinkumar Patel Chief Scientific Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −1,488 | $22.50 | $33.48K | 46,403 |
| Jeegar Pravinkumar Patel Chief Scientific Officer | Jun 22, 2026 | Option exercise | +1,488 | $3.84 | $5.71K | 47,891 |
| Janice Suzann Drew Chief of Dev. Operations | Jun 22, 2026 | Option exercise | +3,839 | $3.84 | $14.74K | 71,633 |
| Janice Suzann Drew Chief of Dev. Operations | Jun 22, 2026 | Sale(10b5-1 plan) | −20,000 | $22.63 | $452.60K | 67,794 |
| Janice Suzann Drew Chief of Dev. Operations | Jun 22, 2026 | Option exercise | +16,161 | $2.99 | $48.32K | 87,794 |
| David E. Cohen Director | Jun 2, 2026 | Sale(10b5-1 plan) | −600 | $21.38 | $12.83K | 17,609 |
| David E. Cohen Director | Jun 2, 2026 | Sale(10b5-1 plan) | −5,456 | $20.21 | $110.27K | 18,209 |
| Luis C. Pena President & CEO, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −16,787 | $22.74 | $381.74K | 637,896 |
| Jeegar Pravinkumar Patel Chief Scientific Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −16,687 | $22.74 | $379.46K | 46,403 |
| Jeegar Pravinkumar Patel Chief Scientific Officer | Jun 1, 2026 | Option exercise | +13,512 | $3.84 | $51.89K | 63,090 |
| Kyle Carver Chief Financial Officer | May 28, 2026 | Sale(10b5-1 plan) | −18,175 | $22.84 | $415.12K | 59,335 |
| Kyle Carver Chief Financial Officer | May 28, 2026 | Option exercise | +15,000 | $2.99 | $44.85K | 77,510 |
| Gregory S. Moss Chief Business & Legal Officer | May 28, 2026 | Sale(10b5-1 plan) | −14,223 | $22.83 | $324.71K | 60,835 |
| Gregory S. Moss Chief Business & Legal Officer | May 28, 2026 | Option exercise | +14,223 | $1.71 | $24.32K | 75,058 |
| 7 Cooperative UA LSP Director, 10% owner | Feb 17, 2026 | Award | +358,680 | $27.88 | $10.00M | 5,288,313 |
| Weegen Felice Isabel Verduyn-van Director, 10% owner | Feb 17, 2026 | Award | +358,680 | $27.88 | $10.00M | 5,288,313 |
| Capital Healthcare Fund LP RA Director | Feb 17, 2026 | Award | +35,868 | $27.88 | $1,000.00K | 2,710,293 |
| Robert Lorne Hopfner Director, 10% owner | Dec 19, 2025 | Buy | +1,000 | $17.35 | $17.35K | 4,026 |
| Janice Suzann Drew EVP, Operations | Dec 9, 2025 | Tax withholding | −5,074 | $17.84 | $90.52K | 67,794 |
| Gregory S. Moss Chief Business & Legal Officer | Dec 9, 2025 | Tax withholding | −13,624 | $17.84 | $243.05K | 60,835 |
| Jeegar Pravinkumar Patel Chief Scientific Officer | Dec 9, 2025 | Tax withholding | −7,513 | $17.84 | $134.03K | 49,578 |
| Eugene Bauer Chief Medical Officer, Director | Dec 9, 2025 | Tax withholding | −1,478 | $17.84 | $26.37K | 270,818 |
| Luis C. Pena President & CEO, Director | Dec 9, 2025 | Tax withholding | −28,138 | $17.84 | $501.98K | 654,683 |
| Kyle Carver Chief Financial Officer | Dec 9, 2025 | Tax withholding | −13,290 | $17.84 | $237.09K | 62,510 |
| Luis C. Pena President & CEO, Director | Nov 7, 2025 | Conversion | +24,225 | – | – | 682,821 |
| 7 Cooperative UA LSP 10% owner | Nov 7, 2025 | Buy | +1,562,500 | $16.00 | $25.00M | 4,929,633 |
| 7 Cooperative UA LSP 10% owner | Nov 7, 2025 | Conversion | +3,367,133 | – | – | 3,367,133 |
| Eugene Bauer Chief Medical Officer, Director | Nov 7, 2025 | Conversion | +25,812 | – | – | 272,296 |
| Kyle Carver Chief Financial Officer | Nov 7, 2025 | Conversion | +3,175 | – | – | 75,800 |
| Ra Capital Management, L.P. Director, 10% owner | Nov 7, 2025 | Buy | +92,904 | $16.00 | $1.49M | 784,345 |
| Ra Capital Management, L.P. Director, 10% owner | Nov 7, 2025 | Buy | +1,157,096 | $16.00 | $18.51M | 2,674,425 |
| Ra Capital Management, L.P. Director, 10% owner | Nov 7, 2025 | Conversion | +691,441 | – | – | 691,441 |
| Ra Capital Management, L.P. Director, 10% owner | Nov 7, 2025 | Conversion | +1,517,329 | – | – | 1,517,329 |
| Robert Lorne Hopfner Director, 10% owner | Nov 7, 2025 | Conversion | +1,632,441 | – | – | 1,632,441 |
| Robert Lorne Hopfner Director, 10% owner | Nov 7, 2025 | Conversion | +294,502 | – | – | 294,502 |
| Robert Lorne Hopfner Director, 10% owner | Nov 7, 2025 | Conversion | +1,441,032 | – | – | 1,441,032 |
| Robert Lorne Hopfner Director, 10% owner | Nov 7, 2025 | Conversion | +3,026 | – | – | 3,026 |
| David E. Cohen Director | Nov 7, 2025 | Conversion | +6,056 | – | – | 23,665 |
| Weegen Felice Isabel Verduyn-van Director, 10% owner | Nov 7, 2025 | Buy | +1,562,500 | $16.00 | $25.00M | 4,929,633 |
| Weegen Felice Isabel Verduyn-van Director, 10% owner | Nov 7, 2025 | Conversion | +3,367,133 | – | – | 3,367,133 |
| Jeegar Pravinkumar Patel Chief Scientific Officer | Nov 7, 2025 | Conversion | +3,175 | – | – | 57,091 |
| Pivotal bioVenture Partners Fund I G.P., L.P. Director, 10% owner | Nov 7, 2025 | Conversion | +294,502 | – | – | 294,502 |
| Pivotal bioVenture Partners Fund I G.P., L.P. Director, 10% owner | Nov 7, 2025 | Conversion | +1,441,032 | – | – | 1,441,032 |
| Pivotal bioVenture Partners Fund I G.P., L.P. Director, 10% owner | Nov 7, 2025 | Conversion | +1,632,441 | – | – | 1,632,441 |
| Janice Suzann Drew EVP, Operations | Nov 7, 2025 | Conversion | +1,587 | – | – | 72,868 |
| Gregory S. Moss Chief Business & Legal Officer | Nov 7, 2025 | Conversion | +3,175 | – | – | 3,175 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
19.29%
3M shares short
Days to cover
3.0
At 1M shares a day
Change since last report
-4.1%
From 4M shares
Short volume, 20 days
49.9%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Evommune's stock actually held short. Settlement fails (shares not delivered on time) peaked at 379 shares on Aug 31, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Janice Suzann Drew Officer | Jun 22, 2026 | 20,000 | $427.20K | Jun 22, 2026 | Exercise of Stock Options |
| David E. Cohen Director | Jun 2, 2026 | 9,258 | $205.25K | Jun 2, 2026 | Pre-IPO Purchase of Common Shares |
| Jeegar Pravinkumar Patel Officer | Jun 1, 2026 | 18,175 | $422.21K | Jun 1, 2026 | Exercise of Stock Options |
| Luis C. Pena Director, Officer | Jun 1, 2026 | 24,225 | $562.75K | Jun 1, 2026 | Pre-IPO Purchase of Common Shares |
| Kyle Carver Officer | May 28, 2026 | 25,675 | $599.25K | May 28, 2026 | Exercise of Stock Options |
| Gregory S. Moss Officer | May 28, 2026 | 14,223 | $331.96K | May 28, 2026 | Exercise of Stock Options |
See a number that looks wrong?